Paul Jeng
Stock Analyst at Guggenheim
(2.93)
# 1,450
Out of 5,115 analysts
6
Total ratings
80%
Success rate
43.36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Paul Jeng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADAG Adagene | Initiates: Buy | $9 | $2.75 | +227.27% | 1 | Nov 24, 2025 | |
| IMTX Immatics | Maintains: Buy | $16 → $19 | $9.55 | +98.95% | 2 | Nov 18, 2025 | |
| IMCR Immunocore Holdings | Assumes: Neutral | n/a | $32.55 | - | 1 | Sep 18, 2025 | |
| CNTX Context Therapeutics | Initiates: Buy | $5 | $2.61 | +91.57% | 1 | Sep 18, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Buy | $50 | $32.19 | +55.33% | 1 | Sep 18, 2025 |
Adagene
Nov 24, 2025
Initiates: Buy
Price Target: $9
Current: $2.75
Upside: +227.27%
Immatics
Nov 18, 2025
Maintains: Buy
Price Target: $16 → $19
Current: $9.55
Upside: +98.95%
Immunocore Holdings
Sep 18, 2025
Assumes: Neutral
Price Target: n/a
Current: $32.55
Upside: -
Context Therapeutics
Sep 18, 2025
Initiates: Buy
Price Target: $5
Current: $2.61
Upside: +91.57%
IDEAYA Biosciences
Sep 18, 2025
Initiates: Buy
Price Target: $50
Current: $32.19
Upside: +55.33%